Injectable thermosensitive hydrogel for local and controlled delivery of siRNA-STAT3 polyplexes to treat

Cristina Casadidio1, Marcel H A M Fens2, Lies A L Fliervoet2

  • 1School of Pharmacy, Drug Delivery Division, University of Camerino, ChIP Research Center, Via Madonna delle Carceri, 62032 Camerino, Macerata, Italy; Department of Pharmaceutical Sciences, Division of Pharmaceutics, Utrecht Institute for Pharmaceutical Sciences (UIPS), Utrecht University, Universiteitsweg 99, 3508, TB, Utrecht, the Netherlands.

Insights

This study developed a dual delivery system using hydrogels to release small interfering RNA (siRNA) polyplexes for ovarian cancer. The system effectively delivered siRNA to tumors, significantly delaying ovarian cancer growth.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Oncology

Background:

  • Advanced-stage ovarian cancer frequently involves metastases, necessitating effective localized therapies.
  • Nucleic acid-based drugs, including siRNA, show promise for treating ovarian cancer and metastatic nodules.
  • Developing advanced drug delivery systems is crucial for localized and sustained therapeutic agent release.

Purpose of the Study:

  • To create and evaluate an injectable, thermosensitive hydrogel system for the sustained, localized release of siRNA polyplexes in the intraperitoneal cavity.
  • To investigate the biodistribution, residence time, and tumor accumulation of siRNA polyplexes delivered via the hydrogel system in a murine ovarian cancer model.
  • To assess the therapeutic efficacy of siRNA-STAT3 delivered by the hydrogel system in delaying ovarian cancer growth.

Main Methods:

  • siRNA was complexed with a cationic diblock copolymer (PD) to form polyplexes, which were then entrapped in an injectable thermosensitive triblock copolymer hydrogel (NPN).
  • Dually labeled polyplexes (siRNA-Cy5.5 and PD-Cy7) were prepared to track biodistribution and tumor accumulation.
  • In vitro rheological tests were performed using patient-derived ascitic fluid; polyplex-hydrogels were then administered intraperitoneally in a murine ovarian cancer model for retention and therapeutic studies.

Main Results:

  • The NPN hydrogel demonstrated stability and performance in a tumor environment.
  • Progressive release of siRNA polyplexes from the hydrogel was observed over seven days, with nanoparticles accumulating in ovarian tumor nodules.
  • siRNA-STAT3 polyplexes released from the hydrogel significantly delayed tumor growth in mice compared to controls.

Conclusions:

  • The developed dual delivery system effectively deposits and penetrates siRNA polyplexes into ovarian tumors and nodules.
  • The injectable thermosensitive hydrogel provides sustained release and localized delivery of siRNA polyplexes.
  • This novel hydrogel-based system shows significant potential for treating advanced ovarian cancer by delaying tumor growth.